OSP Osprey Medical Inc

0.20

0.00 (0.00%)

20 Jan 2025 - Closed

Share Name	Share Symbol	Market	Type
Osprey Medical Inc	ASX:OSP	Australian Stock Exchange	Ordinary Share

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	0.00	0.00%	0.20	0.115	0.23				0.00	00:00:00

Osprey Medical Inc. PRESERV Clinical Trial Update

From Jan 2020 to Jan 2025

In March 2013, Osprey Medical announced commencement of its US registration directed pivotal IDE clinical study of the CINCOR™ system with the first patient enrolled at the Leipzig Heart Centre in Germany.
In May 2013, Dr Richard Heuser enrolled the first two US patients at St. Luke’s Medical Center in Phoenix, Arizona.
As of May 31, 2013, twelve hospitals have Institutional Review Board (IRB) and contract approval and are actively screening patients for trial enrollment.
The CINCOR dye reduction and removal system limits the amount of dye used in a heart procedure from reaching the kidneys, thereby reducing the risk of Contrast Induced Nephropathy (CIN), a form of acute kidney injury, in patients undergoing common heart procedures.